Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | CHRNG | P07510 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRND | Q07001 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084415 | 0.91 | LMNA (0.54) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL9778561 | 0.82 | MAOB (0.50) | ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2084708 | 0.81 | SLC6A2 (0.40) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL6650386 | 0.79 | TAAR1 (0.40) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL14306895 | 0.78 | CYP1A2 (0.42) | MAPK1TSHRSLC6A3SLC6A2CHRNB2 | |
| SCHEMBL5650431 | 0.77 | SLC6A2 (0.40) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL29260166 | 0.76 | ALDH1A1 (0.37) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL31139239 | 0.75 | CHKA (0.37) | ALDH1A1MAPK1LMNAMAPTTSHR | |
| SCHEMBL5616835 | 0.74 | CYP1A2 (0.42) | TSHRSLC6A3SLC6A2CHRNB2CHRNB4 | |
| SCHEMBL9778779 | 0.73 | MAOB (0.52) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | claimed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | claimed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | ALDH1A1 1115/4885MAPK1 594/4885LMNA 3675/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | ALDH1A1 1115/4885MAPK1 594/4885LMNA 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.